The present invention relates to pure 5-HT6 receptor antagonist or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to NMDA receptor antagonist and their use in the treatment of cognitive disorders. The invention further relates to the pharmaceutical composition containing the said combination.